Targeting HER pathway in head and neck and thoracic cancers;Thérapeutiques ciblant la voie des HER dans les cancers ORL et thoraciques

Bulletin du Cancer

Volumn 96, Issue SPEC. ISS., 2009, Pages

  Barlesi, F ^a   Breen, D ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

EGFR; Head and neck cancer; HER2; Lung cancer; Targeted therapy; VEGF

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; LAPATINIB; MATUZUMAB; MOTESANIB; NAVELBINE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PELITINIB; PEMETREXED; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ZALUTUMUMAB;

ADVANCED CANCER; BRONCHUS CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; OVARY CANCER; OVARY CARCINOMA; PATIENT SELECTION; PROSTATE CANCER; REVIEW;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PATIENT SELECTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66249120693     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0774     Document Type: Review

References (69)

1. Italiano A, Besse B, Planchard D, Soria JC. Targeting epidermal growth factor receptor in non-small-cell lung cancer: current advances and perspectives. Bull Cancer 2007 ; 94 : F177-F188. (Pubitemid 350131942)
2. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne P, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006 ; 24 : 5253-5258 (Pubitemid 46631370)
3. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin (C) / vinorelbine (V) compared with CV alone as first line therapy in (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2008 ; 19 : 362-369
4. Butts CA, Bodkin D, Middleman E, et al. Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 2005 ; 25 : 5777-5784
5. Kelly K, Herbst R, Crowley J, McCoy J, Atkins J, Lara P, et al. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced NSCLC: a randomized phase II selectional trial SWOG 0342. J Clin Oncol 2006 (ASCO Annual Meeting Proceedings 18S:7015).
6. Lynch TJ, Patel T, Dreisbach L, et al. Overall Survival (os) Results from the Phase III Trial BMS 099: Cetuximab+Taxane/Carboplatin As 1st-line Treatment for Advanced NSCLC. J Thorac Oncol 2008 ; 3 : S305.
7. Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first line treatment of patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2008 (ASCO Annual Meeting Proceedings 26: Abstract 3).
8. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2005 ; 23 : 8646-8654 (Pubitemid 46211507)
9. Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med 2008 ; 359 : 1116-1127
10. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 ; 354 : 567-578 (Pubitemid 43209104)
11. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006 ; 17 : 1007-1013
12. Bastholt L, Specht L, Jensen K, Brun E, Loft A, Petersen J, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007 ; 85 : 24-28 (Pubitemid 47562580)
13. Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, et al. Lack of trastuzumab activity in non-small-cell lung carcinoma with overexpression of ERBB2:39810: a phase II trial of Cancer and Leukemia Group B. Cancer 2005 ; 103 : 1670-1675
14. Krug LM, Miller VA, Patel J, Crapanzano J, Azzoli CG, Gomez J, et al. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced non-small-cell lung carcinoma. Cancer 2005 ; 104 : 2149-2155 (Pubitemid 41579961)
15. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004 ; 15 : 19-27. (Pubitemid 38139598)
16. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with HER2-overexpressing, untreated, advanced non-small-cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with HER2-overexpressing disease. Lung Cancer 2004 ; 44 : 99-110. (Pubitemid 38317266)
17. Cappuzzo F, Bermis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006 ; 354 : 2619-2621 (Pubitemid 43882374)
18. Johnson BE, Janne PA. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small-cell lung cancer. Clin Cancer Res 2006 ; 12 : 4436-4440
19. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005 ; 366 : 1527-1537
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 ; 353 : 123-132 (Pubitemid 41058344)
21. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K, SIGN Study Group. Phase II, open label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second line therapy in patients with advanced (stages IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006 ; 17 : 401-409 (Pubitemid 44309982)
22. Niho S, Ychinose Y, Tamura T, et al. Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 2007 (ASCO Annual Meeting Proceedings 25: LBA7509).
23. Douillard JY, Kim E, Hirsh V, et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatitc non-small-cell lung cancer pretreated with platinum based chemotherapy: a randomized, open label phase III study (INTEREST). J Thorac Oncol 2007 ; 2 : S305 (PRS02).
24. Herbst R, O'Neill V, Fehrenbacher L, Belani CP, Bonomi P, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007 ; 25 : 4743-4750 (Pubitemid 350086476)
25. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (avastin®) in combination with erlotinib (tarceva®) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (beta). J Thorac Oncol 2008 ; 3 : s302.
26. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004 ; 22 : 777-784 (Pubitemid 41103588)
27. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004 ; 22 : 785-794 (Pubitemid 41103589)
28. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005 ; 23 : 5892-5899 [Epub ahead of print]. (Pubitemid 46300205)
29. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007 ; 25 : 1545-1552 (Pubitemid 46733081)
30. Giaccone G, Gallegos Ruiz M, Lechevalier T, Thatcher N, Smit E, Rodriguez J, et al. Erlotinib for front line treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006 ; 12 : 5919-5920
31. Kasahara K, Kimura H, Yoshimoto A, Sone T, Shibata K, Ishiura Y, et al. A phase II study of gefitinib monotherapy for chemotherapy-naïve patients with NSCLC. J Clin Oncol 2005 (ASCO Annual Meeting Proceedings 23: Abstract 7074).
32. Suzuki R, Hasegawa Y, Baba K, Saha H, Saito H, Tanuguchi H, et al. A phase II study of single-agent gefitinib as first line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer 2006 ; 94 : 1599-1603 (Pubitemid 43924920)
33. Reck M, Buchholz E, Schott-von-Römer K, Krützfeldt K, Gatzemeier U, Manegold M. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stages III/IV non-small-cell lung cancer. Clin Lung Cancer 2006 ; 7 : 406-411 (Pubitemid 44043551)
34. Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, et al. First line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006 ; 24 : 64-69 (Pubitemid 46630495)
35. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, et al. Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007 ; 25(7) : 760-766 (Pubitemid 350002874)
36. Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, et al. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemo-naive patients with advanced non-small-cell lung cancer. Cancer 2006 ; 107 : 1873-1882 (Pubitemid 44582958)
37. Lin WC, Chiu CH, Liou JL, Chen YM, Perng RP, Tsai CM. Gefitinib as front line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer 2006 ; 54 : 193-199
38. Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, et al. A phase II trial of gefitinib as first line therapy for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006 ; 95 : 998-1004. (Pubitemid 44606825)
39. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006 ; 24 : 3340-3346 (Pubitemid 46638887)
40. Paez-Ares L, Sanchez JM, García-Velasco A, Massuti B, López-Vivanco G, Provencio M, et al. A prospective phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006 (ASCO Annual Meeting Proceedings 18S:7020).
41. Cappuzzo F, Toschi L, Trisolini R, Bemis L, Sujita M, Domenichini I, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007 ; 25 : 2248-2255 (Pubitemid 46954651)
42. Kelly K, Gaspar LE, Chansky KL, et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation and IRESSA/placebo maintenance in patients with inoperable stage III NSCLC. J Clin Oncol 2005 (ASCO Annual Meeting Proceedings 23: Abstract 7058).
43. Kris MG, Pao W, Zakowski MF, Ladanyi M, Heelan RT, Schwartz L, et al. Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy. J Clin Oncol 2006 (ASCO Annual Meeting Proceedings 18S: 7021).
44. Tsuboi M, Kato H, Nagai K, Tsuchiya R, Wada H, Tada H, et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small-cell lung cancer. Anticancer Drugs 2005 ; 16 : 1123-1128 (Pubitemid 41565778)
45. Miller V, Kris M, Shah N, Patel J, Azzoli C, Gomez J, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004 ; 22 : 1103-1109 (Pubitemid 41095044)
46. West H, Franklin W, McCoy J, Gumerlock P, Vance R, Lau D, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006 ; 24 : 1807-1813 (Pubitemid 46638977)
47. Cadranel J, Quoix E, Debove P, Moro-Sibilot D, Bréchot JM, Souquet PJ, et al. IFCT0401 trial: phase II study of gefitinib administered as first line treatment in non-resectable, pneumonic-type adenocarcinoma (P-ADC). J Clin Oncol 2006 (ASCO Annual Meeting Proceedings 18S: 7186).
48. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005 ; 11 : 8418-8424 (Pubitemid 41746956)
49. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004 ; 22 : 77-85. (Pubitemid 41095117)
50. Doss HH, Greco FA, Meluch AA, Gray JR, Spigel DR, Shipley DL, et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2006 ; 24 : 290s (abstract 5543).
51. Ross HJ, Blumenschein GR, Dowlati A, Aisner J, Rigas JR, Stanislaus M, et al. Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2005 (ASCO Annual Meeting Proceedings 16S:7099).
52. Abidoye OO, Cohen EE, Wong SJ, Kozloff MF, Nattam SR, Stenson KM, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006 ; 24 : 297s (abstract 5568).
53. Harrington KJ, Bourhis J, Nutring CM, Rosine D, Theodosio AM, Gardiner S, et al. A phase I, open label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006 ; 24 : 293s (abstract 5553).
54. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006 (ASCO Annual Meeting Proceedings 18S).
55. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007 ; 25 : 4270-4277 (Pubitemid 47548567)
56. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007 ; 25 : 4278-4284 (Pubitemid 47548568)
57. Penault-Llorca F. Targeted therapies: the question of target detection and evaluation. Bull Cancer 2007 ; 94 : F245-F248. (Pubitemid 350131952)
58. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli G, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005 ; 97 : 643-655 (Pubitemid 40812628)
59. Sone T, Kasahara K, Kimura H, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 2007 ; 109 : 1836-1844 (Pubitemid 46668548)
60. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008 ; 26 : 4268-4275
61. Hamilton M, Wolf JL, Rusk J, Beard S, Clark GM, Witt K, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006 ; 12 : 2166-2171
62. Pham D, Kris MG, Riely G, Sarkaria I, McDonough T, Chuai S, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006 ; 24 : 1700-1704 (Pubitemid 46622141)
63. Satouchi M, Negoro S, Funada Y, Urata Y, Shimada T, Yoshimura S, et al. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer 2007 ; 96 : 1191-1196 (Pubitemid 46625078)
64. Pérol M, Arpin D. Angiogenesis and lung cancer. Bull Cancer 2007 ; 94 : S220-31.
65. Barlesi F, Tchouhadjian C, Doddoli C, Torre JP, Astoul P, Kleisbauer JP. CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer 2005 ; 92 : 13-14 (Pubitemid 40188428)
66. Perez-Soler R, Saltz L. Cutaneous adverse effects with HERl/EGFR targeted agents: is there a silver lining? J Clin Oncol 2005 ; 23 : 5235-5246
67. Barlesi F, Tchouhadjian C, Doddoli C, Torre JP, Astoul P, Kleisbauer JP. CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer 2005 ; 92 : 13-14 (Pubitemid 40188428)
68. Perez-Soler R, Saltz L. Cutaneous adverse effects with HERl/EGFR targeted agents: is there a silver lining? J Clin Oncol 2005 ; 23 : 5235-5246
69. Gatzemeier U, von Pawel J, Vynnchenko I, et al. FLEX: Cetuximab in Combination with Platinum-Based Chemotherapy (CT) Improves Survival Versus CT Alone in the 1st-line Treatment of Patients (pts) with Advanced Non-small Cell Lung Cancer (NSCLC). J Thorac Oncol 2008 ; 3 : S265.